Medicine and Dentistry
Melanoma
100%
Neoplasm
57%
Diseases
56%
Sentinel Node
47%
Recurrent Disease
29%
Metastatic Carcinoma
26%
Retroperitoneal Lymph Node Dissection
23%
Carcinoma
23%
Radiation Therapy
22%
Biopsy Technique
16%
Common Bile Duct
16%
Interferon
15%
Lymph Node
14%
Surgical Margin
14%
Adjuvant Therapy
13%
Sentinel Lymph Node
13%
Adenocarcinoma
12%
Neck
12%
Lymphatic Drainage
12%
Connective Tissue Cancer
12%
Overall Survival
12%
Lymphoscintigraphy
11%
Obstruction
11%
Mastectomy
11%
Lymph Duct
11%
Computer Assisted Tomography
11%
Sentinel Lymph Node Biopsy
11%
Colon
11%
Rectum Cancer
10%
Merkel Cell Carcinoma
10%
Intraductal Carcinoma
10%
Vulva
10%
Papilloma
10%
Squamous Cell Carcinoma
10%
Desmoid Tumor
10%
Surgical Emergency
10%
Lymphocyte
10%
Postoperative Complication
9%
Malignant Neoplasm
9%
Cholecystectomy
9%
Cytotoxicity
9%
Quadrantectomy
9%
Cancer
9%
Prognostic Factor
8%
Lymph Node Metastasis
8%
Breast Cancer
8%
Symptomatic Treatment
8%
Disease Free Survival
8%
Wound Infection
8%
Melanoma Skin Cancer
7%
Keyphrases
Melanoma
64%
Sentinel Lymph Node
47%
Tumor
39%
Malignant Melanoma
27%
Breast
23%
Metastatic Melanoma
22%
Melanoma Patients
21%
Adjuvant Therapy
17%
Sentinel Lymph Node Biopsy
16%
Common Bile Duct
16%
Locomotion
15%
Interferon-α (IFN-α)
15%
Computed Tomography
14%
Axillary Lymph Node Dissection
13%
Radiation Therapy
12%
Carcinoma
12%
Sarcoma
12%
Lymphoscintigraphy
12%
High-dose Interferon
12%
Lymphatic Drainage
12%
Failure Pattern
11%
Breast Carcinoma
11%
Completion Lymph Node Dissection
11%
Mastectomy
10%
Disease-free Survival
10%
Metastasis
10%
Prognostic Factors
10%
Head-and-neck
10%
Papilloma
10%
Merkel Cell Carcinoma
10%
Ductal Carcinoma in Situ
10%
Histology
10%
Growth Inhibition
10%
Medical Center
9%
Disease-specific Survival
9%
Blue Dye
9%
Collagen
9%
Cholecystectomy
9%
Wide Local Excision
9%
Melanoma Cells
9%
Groin
9%
Lymph Node Dissection
8%
Adenocarcinoma
8%
Radiotherapy
8%
Oncologic
8%
Lymph Node Metastasis
8%
Wound Infection
8%
Delayed Diagnosis
8%
Desmoid Tumor
7%
Consecutive Patients
7%